The CDC has approved the expanded use of RSV and meningococcal vaccines from Pfizer, Moderna, and GSK, even as its advisory panel considers major changes. Adults aged 50-59 at risk can now get RSV shots. GSK's new 5-in-1 meningococcal vaccine also received backing. Moderna saw extremely bullish sentiment on Stocktwits after the update.